CCTG LY.12

**Time:** Monday, December 5, 2016: 8:15 AM  
**Location:** Pacific Ballroom 21-22 (Marriott Marquis San Diego Marina)  
**Type:** Oral Presentation  
**Session:** 902 - Health Services Research—Malignant Conditions: Innovations in Detection, Management, and Outcomes  
**Presenter:** Tanya Skamene  

**Abstract:** *Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial (#690)*  

**Authors:** Tanya Skamene, Wenyu Jiang, Ralph M. Meyer, Michael Crump, John Kuruvilla, C. Tom Kouroskis, Stefano Luminari, Stephen Couban, Matthew C. Cheung, David A Rizzieri, Peter G Bardy, FRCPA11*, Joseph Pater, Marina S. Djurfeldt, Lois E. Shepherd, Bingshu E Chen, and Annette E Hay  

**Link:** [https://ash.confex.com/ash/2016/webprogram/Paper88925.html](https://ash.confex.com/ash/2016/webprogram/Paper88925.html)

---

CCTG LY.15

**Time:** Monday, December 5, 2016: 6:00 – 8:00 PM  
**Location:** Hall GH (San Diego Convention Center)  
**Type:** Poster  
**Session:** 624 - Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III  
**Presenter:** Kerry Savage  

**Abstract:** *A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15 (#4162)*  

**Authors:** Tony Reiman, Kerry J. Savage, Michael Crump, Matthew Cheung, David A. MacDonald, Rena Buckstein, Stephen Couban, Eugenia Piliotis, Kevin R Imrie, David Spaner, Sudeep Shivakumar, John Kuruvilla, Diego Villa, Lois E. Shepherd, Tanya Skamene, Chad Winch, Bingshu E Chen, and Annette E Hay  

**Link:** [https://ash.confex.com/ash/2016/webprogram/Paper89956.html](https://ash.confex.com/ash/2016/webprogram/Paper89956.html)
ECOG 2496 / CCTG HD.7

Time: Sunday, December 4, 2016: 6:00 – 8:00 PM  
Location: Hall GH (San Diego Convention Center)  
Type: Poster  
Session: 624 - Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II  
Presenter: Jennifer A. Kanakry  
Abstract: Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial (#2992)  
Link: https://ash.confex.com/ash/2016/webprogram/Paper94876.html

SWOG S9704 / CCTG LY.11

Time: Monday, December 5, 2016: 6:00 – 8:00 PM  
Location: Hall GH (San Diego Convention Center)  
Type: Poster  
Session: 731. Clinical Autologous Transplantation: Results: Poster III  
Presenter: Patrick Stiff  
Abstract: Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis (#4651)  
Link: https://ash.confex.com/ash/2016/webprogram/Paper91539.html

SWOG 1203 / CCTG ALC.3

Time: Monday, December 5, 2016: 2:45 PM  
Location: San Diego Ballroom AB (Marriott Marquis San Diego Marina)  
Type: Oral Presentation  
Session: 616 - Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Clinical Trials of Novel Drugs and Combinations in AML  
Presenter: Guillermo Garcia-Manero  
Abstract: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML) (#901)  
Link: https://ash.confex.com/ash/2016/webprogram/Paper96748.html
Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat (#1166)